Magnetar Financial LLC
Institutional investor · Portfolio as of Q2 2019
Top Holdings435 positions
WELLCARE HEALTH PLANS INC | 912,876 | $260.2M | 5.2% | — | — | 1 qtr | First report 0 |
FIRST DATA CORP NEW | 8.5M | $230.4M | 4.6% | — | — | 1 qtr | First report 0 |
VANTIV INC | 1.9M | $228.8M | 4.6% | — | — | 1 qtr | First report 0 |
TOTAL SYS SVCS INC | 1.7M | $224.1M | 4.5% | — | — | 1 qtr | First report 0 |
WABCO HLDGS INC | 1.7M | $220.8M | 4.4% | — | — | 1 qtr | First report 0 |
RED HAT INC | 1.1M | $212.2M | 4.2% | — | — | 1 qtr | First report 0 |
TRIBUNE MEDIA CO | 4.3M | $198.7M | 4.0% | — | — | 1 qtr | First report 0 |
CYPRESS SEMICONDUCTOR CORP | 8.5M | $189.3M | 3.8% | — | — | 1 qtr | First report 0 |
MELLANOX TECHNOLOGIES LTD | 1.7M | $187.8M | 3.8% | — | — | 1 qtr | First report 0 |
CELGENE CORP | 1.9M | $174.2M | 3.5% | — | — | 1 qtr | First report 0 |
TABLEAU SOFTWARE INC | 1M | $173.3M | 3.5% | — | — | 1 qtr | First report 0 |
ALLERGAN PLC | 966,272 | $161.8M | 3.2% | — | — | 1 qtr | First report 0 |
| 13.2M | $156.1M | 3.1% | — | — | 1 qtr | First report 0 | |
| 23.5M | $154.6M | 3.1% | — | — | 1 qtr | First report 0 | |
| 3.2M | $148.4M | 3.0% | — | — | 1 qtr | First report 0 | |
VERSUM MATLS INC | 2.8M | $143.3M | 2.9% | — | — | 1 qtr | First report 0 |
ANADARKO PETE CORP | 1.7M | $123.5M | 2.5% | — | — | 1 qtr | First report 0 |
ADVANCED DISP SVCS INC DEL | 3.7M | $119.5M | 2.4% | — | — | 1 qtr | First report 0 |
FINISAR CORPATION | 5.1M | $117.4M | 2.4% | — | — | 1 qtr | First report 0 |
SPARK THERAPEUTICS INC | 885,199 | $90.6M | 1.8% | — | — | 1 qtr | First report 0 |
Magnetar Financial LLC manages $5B across 435 positions as of Q2 2019. Top holdings: WCG (5.2%), FDC (4.6%), WP (4.6%). Fund DNA: Momentum Trader. HoldingsIntel Score: 3/5.0.
First quarter we have for this fund: 435 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $5.0B across 435 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR